IFNA2 and lymphoma: A CD20-targeting immunocytokine utilizing the IFN-α2 subtype decreased the 50% inhibitory concentration (IC50) compared to commercially available forms of IFN-α, increased antibody-dependent cellular cytotoxicity (ADCC) against lymphoma cells (with a decreased complement-dependent cytotoxicity (CDC)), and prolonged survival in murine groups treated with the immunocytokine compared to equal concentrations of parental IFN-α and antibody [63].